Who Paid My Doc
Katie Buckner
Sleep Medicine Abingdon, VA Doctor of Osteopathy
NPI 1558891101 CMS profile 3746305
16000 Johnston Memorial Dr, Abingdon, VA 24211
General payments
$12
Research payments
$0
Ownership & investment interest
$0
Through program year 2020, Katie Buckner of Abingdon, VA is reported in the CMS Open Payments database as having received $12 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 1st percentile of Sleep Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2020 | General | $12 | 1 |
Beside peers
- Katie Buckner
- Sleep Medicine median
- Middle half of Sleep Medicine
- National median
In program year 2025, general payments to Katie Buckner were reported at $0. Among 184 Sleep Medicine profiles paid that year, the median was $557 and the middle half received between $150 and $1,388.
Show as a table
| Year | Katie Buckner | Sleep Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $170 | $52–$432 | $163 |
| 2020 | $12 | $103 | $25–$262 | $114 |
| 2021 | $0 | $160 | $67–$690 | $132 |
| 2022 | $0 | $217 | $54–$1,038 | $149 |
| 2023 | $0 | $301 | $125–$877 | $160 |
| 2024 | $0 | $333 | $95–$956 | $164 |
| 2025 | $0 | $557 | $150–$1,388 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 117 drugsPart D claims
6,561
Drug cost
$305,219
Branded share of claims
23.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 72 | $56,057 | |
| Spiriva Respimat Tiotropium Bromide | Brand | 42 | $25,318 | |
| Eliquis Apixaban | Brand | 15 | $23,185 | |
| Jardiance Empagliflozin | Brand | 43 | $22,927 | |
| Pradaxa Dabigatran Etexilate Mesylate | Brand | 65 | $17,689 | |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | Brand | 18 | $12,230 | |
| Humulin N Insulin Nph Human Isophane | Brand | 66 | $11,042 | |
| Humulin N Kwikpen Insulin Nph Human Isophane | Brand | 35 | $9,761 | |
| Wixela Inhub Fluticasone Propion/Salmeterol | Brand | 33 | $9,333 | |
| Victoza 2-Pak Liraglutide | Brand | 13 | $8,022 |
The 10 drugs with the highest cost, of 117 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Sleep Medicine in Virginia
Related records
Sleep Medicine in Virginia
Practitioners in the same specialty and state, ranked by reported value.
All Sleep Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Virginia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.